KRAS somatic mutations are found in 30-40% of colorectal cancer (CRC). Seven mutations in codons 12 and 13 of KRAS (95% of the observed human mutations) preclude the efficacy of anti-EGFR therapy for the treatment of CRC. Assessment of KRAS mutational status has become a standard procedure in the management of patients with CRC. Technically, KRAS mutation testing can be performed with different methods, characterized by distinct sensitivities and specificities.
Tissue specimen reqiured through operative procedure
Download the free health test app from Dr. B. Lal Clinical Laboratory. Find all the healthcare information and needs you require in just one place. You can schedule home collection, see reports, save medical history, search for more than 1800 tests, and more with just one app. Available both on iOS and Android. Simplify healthcare, download the Dr. B. Lal Clinical Lab App.